Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cytokinetics, Incorporated - Common Stock (NQ:CYTK)

78.65 +0.27 (+0.34%)
Streaming Delayed Price Updated: 9:44 AM EDT, Jul 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cytokinetics, Incorporated - Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
News headline image
Cell Analysis Instruments Provider Cytek Biosciences Kick Starts Trading After Pricing IPO At $17 ↗
Cytek Biosciences Inc (NASDAQ: CTKB) shares started trading today after its initial public offering was priced to raise about $200 million for the cell-analysis Company.... 
Via Benzinga
Topics Initial Public Offering
News headline image
Why Cytokinetics (CYTK) Shares Are Trading Higher Today? ↗
Cytokinetics Incorporated (NASDAQ: CYTK) shares continue to move forward after it announced positive REDWOOD-HCM Phase 2 data for CK-274 and garnered favorable comments... 
Via Benzinga
News headline image
10 Biggest Price Target Changes For Tuesday ↗
Citigroup boosted International Business Machines Corporation (NYSE: 
Via Benzinga
News headline image
Why Is Cytokinetics Inc. (NASDAQ: CYTK) The Best Stock of the Day? ↗
Founded in 1997, Cytokinetics Inc. focuses on muscle biology, developing muscle activators and inhibitors that improve overall function. These medications most often serve... 
Via Benzinga
News headline image
Dow on Pace for Worst Day of 2021 as Covid-19 Fears Weigh ↗
The Dow Jones Industrial Average is down more than 760 points at midday and is eyeing its worst daily drop for 2021. 
Via Talk Markets
Topics Stocks
News headline image
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge ↗
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19) Cytokinetics, Incorporated... 
Via Benzinga
News headline image
54 Biggest Movers From Yesterday ↗
Gainers Aehr Test Systems (NASDAQ: AEHR) shares climbed 87.9% to close at $6.39 on Monday after the company won a $10.8 million single purchase order from its lead silicon... 
Via Benzinga
News headline image
Here's Why Cytokinetics Is Rocketing Higher Today ↗
The company's new heart drug candidate produced encouraging clinical trial results. 
Via The Motley Fool
News headline image
Mid-Day Market Update: Crude Oil Dips 6%; Cytokinetics Shares Spike Higher ↗
Midway through trading Monday, the Dow traded down 2.28% to 33,896.40 while the NASDAQ fell 1.31% to 14,238.93. The S&P also fell, dropping 1.74% to 4,251.79. The U.S. has the... 
Via Benzinga
Topics Stocks
News headline image
30 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Cytokinetics, Incorporated (NASDAQ: CYTK) jumped 56.4% to $30.07 after the company disclosed topline results from Cohorts 1 and 2 of REDWOOD-HCM. Aehr Test Systems (... 
Via Benzinga
News headline image
CYTK Stock Flies High on Exciting Drug Trial Results ↗
CYTK stock is being boosted by bullish biopharma buyers today. The company is reporting with optimism regarding its newest HCM treatment. 
Via InvestorPlace
News headline image
How Strong Cytokinetics Test Results Could Undermine Bristol Myers' $13.1 Billion Buyout ↗
Cytokinetics said Monday its treatment improved blood flow for patients with a genetic heart disease, and the biotech stock sprinted. 
Via Investor's Business Daily
News headline image
Mid-Morning Market Update: Markets Open Lower; AutoNation Profit Beats Estimates ↗
Following the market opening Monday, the Dow traded down 2.31% to 33,885.81 while the NASDAQ fell 1.67% to 14,186.04. The S&P also fell, dropping 1.94% to 4,243.38. The U.S.... 
Via Benzinga
Topics Stocks
News headline image
Stocks That Hit 52-Week Highs On Monday ↗
On Monday morning, 20 companies achieved new highs for the year. Areas of Significance: The largest company by market cap to break to a new 52-week high was PepsiCo... 
Via Benzinga
News headline image
Cytokinetics Shares Gain On Positive Data From Heart Disease Candidate ↗
Cytokinetics Incorporated (NASDAQ: CYTK) has announced positive topline results from Cohorts 1 and 2 of REDWOOD-HCM Phase 2 trial of CK-3773274 (CK-274) in... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Gainers NRX Pharmaceuticals (NASDAQ:NRXP) stock moved upwards by 67.6% to $14.28 during Monday's pre-market session. The company's market cap stands at $684.2... 
Via Benzinga
News headline image
Cytokinetics Post-Hoc Data Suggests Omecamtiv Mecarbil Works Better In High-Risk Patients For Heart Failure ↗
Cytokinetics Incorporated (NASDAQ: CYTK) announced secondary data analysis from the GALACTIC-HF trial evaluating omecamtiv mecarbil in patients with heart... 
Via Benzinga
News headline image
Cytokinetics Inc (CYTK) Q1 2021 Earnings Call Transcript ↗
CYTK earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Astellas Walks Away From $450M Research & Discovery Partnership With Cytokinetics ↗
Cytokinetics Inc (NASDAQ: CYTK) revealed in an SEC filing that Astellas Pharma Inc (OTCMKTS: ALPMY) is walking away from a pact to research and... 
Via Benzinga
Topics Regulatory Compliance
News headline image
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.